Insmed Inc. Welcomes Studies Linking IGFBP-3 to Prevention of Blindness in Premature Infants

    Key Protein in Company's Drug IPLEX(TM) is Seen Playing Lead Role in
Development of Healthy Eyesight

    RICHMOND, VA., June 26 /CNW/ - Insmed Incorporated (Nasdaq:  INSM), a
biopharmaceutical company focused on the development and approval of drugs for
the treatment of metabolic diseases with unmet medical needs, today noted the
publication of promising results of research from three universities regarding
the potential role of insulin-like growth factor binding protein-3 (IGFBP-3)
in the prevention of blindness among premature infants.

    IGFBP-3 is a key component of Insmed's lead drug candidate, IPLEX(TM),
which has been approved by the U.S. Food and Drug Administration for the
treatment of a severe growth disorder and is currently being studied as a
treatment for myotonic muscular dystrophy, HIV-associated adipose
redistribution syndrome and retinopathy of prematurity (ROP). IPLEX(TM) is the
combination of IGFBP-3 with recombinant human insulin-like growth factor 1

    The new study results, published in the June 19 issue of the Proceedings
of the National Academy of Sciences, focus on the action of IGFBP-3 in
promoting normal tissue growth and preventing ROP. Researchers at the
University of Florida reported that mice treated with IGFBP-3 showed
closer-to-normal growth of retinal vasculature than mice without IGFBP-3 in
similar high-oxygen conditions. Researchers at Harvard Medical School and the
University of Goteborg in Sweden reported similar results.

    In addition, Harvard Medical School researchers, in collaboration with
researchers at the University of Goteborg, reported results of a clinical
study showing IGFBP-3 levels in infants with ROP were lower than those of
healthy babies. The researchers said these results suggest that IGFBP-3,
acting independently of IGF-I, helps prevent oxygen-induced loss of
blood-vessels and helps promote vascular re-growth.

    Insmed Chairman and CEO Geoffrey Allan, Ph.D., commented: "These studies
by researchers at three distinguished universities mark an important
scientific milestone in Insmed's development of IPLEX(TM) as a treatment for
ROP. They suggest that IGFBP-3, once thought only to regulate IGF-I, actually
plays a broader role in human development and in the growth or regeneration of
human tissues. Not only is this discovery important in the fight against ROP,
but it also suggests promising avenues for research into the treatment of
other conditions associated with ischemia and vascular damage."

    About IPLEX(TM) and ROP

    IPLEX(TM) is currently in the first phase of clinical development for the
treatment of ROP, a disease that affects an estimated 14,000 to 16,000
premature infants each year. ROP impedes the development of the small blood
vessels in the back of the eye, leading to blindness in severe cases. A Phase
I clinical study investigating IPLEX(TM) as a treatment for ROP is underway at
the University of Goteborg, in collaboration with scientists at the Harvard
Medical School. Ten patients will be enrolled with the objective of the study
being to determine the dose of IPLEX(TM) required to increase serum IGF-I
levels into the normal physiological range. This study is expected to be
completed by the end of 2007.

    About Insmed

    Insmed is a biopharmaceutical company focused on the development and
approval of drugs for the treatment of metabolic diseases with unmet medical
needs. For more information, please visit To be added to
Insmed's investor lists, please contact Haris Tajyar at or
at 818-382-9702.

    Forward Looking Statements

    This release contains forward-looking statements which are made pursuant
to provisions of Section 21E of the Securities Exchange Act of 1934. Investors
are cautioned that such statements in this release, including statements
relating to planned clinical study design, regulatory and business strategies,
plans and objectives of management and growth opportunities for existing or
proposed products, constitute forward-looking statements which involve risks
and uncertainties that could cause actual results to differ materially from
those anticipated by the forward-looking statements. The risks and
uncertainties include, without limitation, risks that product candidates may
fail in the clinic or may not be successfully marketed or manufactured, the
Company may lack financial resources to complete development of product
candidates, the FDA may interpret the results of studies differently than the
Company, competing products may be more successful, demand for new
pharmaceutical products may decrease, the biopharmaceutical industry may
experience negative market trends and other risks and challenges detailed in
the Company's filings with the U.S. Securities and Exchange Commission,
including the Company's Quarterly Report on Form 10-Q for the quarter ended
March 31, 2007. Readers are cautioned not to place undue reliance on any
forward-looking statements which speak only as of the date of this release.
The Company undertakes no obligation to publicly release the results of any
revisions to these forward-looking statements that may be made to reflect
events or circumstances that occur after the date of this release or to
reflect the occurrence of unanticipated events.

For further information:

For further information: Investor Relations International Haris Tajyar,

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890